In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

ACVC highlights new aspects in 2020 ESC ACS guidelines

The new 2020 Acute Coronary Syndromes (ACS) in Patients Presenting without Persistent ST-Segment Elevation (Management of) Guidelines have just been released.

Ingo Ahrens 2019.pngProf. Ingo Ahrens, Germany

ACVC Research section chairperson



The new 2020 ESC Guidelines on NSTE-ACS have just been released.

We will highlight the major changes for the recommendations in acute cardiovascular care referring to the antithrombotic and invasive treatment of these patients.

A new class III recommendation clearly states that pre-treatment with a P2Y12 receptor antagonist should not be done in patients in whom the coronary anatomy is not known and early invasive treatment is planned.

For NSTE-ACS patients with an indication for oral anticoagulation who PCI and stent implantation, a new class I recommendation advises keeping the duration of “triple” therapy (DAPT + OAC) to a minimum of one week or until hospital discharge (whatever comes first).

This ensures a clear dual antithrombotic treatment strategy for the post-ACS phase consisting of preferably a NOAC and clopidogrel for up to 12 months in patients without a perceived high bleeding risk and low thromboembolic risk.
An early invasive strategy within 24 hours is now the clear preference (class I recommendation) for patients with NSTEMI or ACS patients with transient ECG changes indicating myocardial ischemia or ACS patients with a GRACE risk score > 140.

The wider span of the 72h interval in intermediate-risk patients is not recommended anymore and simplifies the decision whether a patient should undergo early invasive treatment or whether the patient is at such a low risk that alternative testing for coronary artery disease (CAD) with non-invasive methods (e.g. coronary computed tomography angiography, CCTA) may be considered instead of invasive treatment.